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Collaborative Study
• School of Pharmacy and Lewis College of Business, Marshall University, 
Marshall Health, Valley Health Systems, Thomas Memorial Health 
System
• The purpose of ongoing research is to analyze and quantify the financial 
impact and humanistic and challenges concerning the 340B program in 
the tri-state [ KY, OH, and WV] and quantify how program is meeting its 
intent in this area.
• In-progress analysis:  financial impacts for institutions
• Analysis of the impact to patients via sliding scale pricing
Introduction
• One third of Americans are living at 
or below 200% of the FPL and 
struggle to afford prescriptions
• Many Americans fall in the gap 
between Medicaid and fully insured = 
“the working poor” or “vulnerable 
populations”
• This program targets assistance for 
this population and allows qualifying 
facilities to fund care and expand 
services for patients that are unable 
to pay. 
Introduction: Timeline of the 340B Program
• 1990 - US created Medicaid Rebate 
Program
• 1992 - Veterans Health Care Act of 
1992 established the 340B Drug 
Pricing Program in section 340B of 
the Public Health Service Act 
(PHSA)
• 1996 - 340B expanded by HRSA to 
allow a single “contract pharmacy”
• 2010 - 340B revised as part of the 
ACA to allow multiple contract 
pharmacies
• 2018 – CMS proposed significant 
cuts to the program
Introduction
• The Intent of program 340 is to allow covered entities to stretch scarce 
federal resources as far as possible, reaching more eligible patients and 
providing more comprehensive services.
• Program helps to reduce outpatient drug costs for safety net providers, 
including Title X agencies and their patients by statutorily mandating deep 
discounts from drug manufacturers as a condition of Medicaid 
reimbursement.
• Providers typically save 20-50% on outpatient drug costs (known as a 
ceiling price) through participation in the program. These savings can be 
used to reduce the price of pharmaceuticals for patients, expand services 
offered to patients, or provide services to more patients.
https://www.hhs.gov/opa/grants-and-funding/340b-drug-pricing-program/index.html
Why Participate? –> Pricing = Lowest in Market
Introduction: 340B Covered Outpatient Drugs:  What is 
Included and What is Not Included?
340B Eligibility: Who is Eligible? 
Federal Grantees / Designees Certain Hospitals
Federally qual fied health center Disproportionate share hospitals
Federally qualified health center lookalikes Children’s hospitals
Title X family planning grantees Critical access hospitals
State aids drugs assistance programs Free standing cancer hospitals
Ryan white care act grantees (A,B,C,D,F) Rural referral centers
Black lung clinics Sole community hospitals
Hemophilia treatment centers
Native Hawaiian health centers
Urban Indian organizations
Sexually transmitted disease grantees
Tuberculosis grantees
https://www.hrsa.gov/opa/eligibility-and-registration/index.html
Introduction: Eligibility for the Program
Methodology
• Primary Hypothesis:  Participation in the 340B 
program benefits both patients and health 
systems and has aided in expansion of access 
to medications and expanded health care 
services, and  improved financial viability to 
health systems. 
• The methodology for this qualitative study was 
a literature review complemented with semi 
structed interviews and analysis of the impact 
of the program with Marshall University 
affiliates,
• Databases searched: PubMed, EbscoHost, 
ProQuest, CINHAL, Alt-Health Watch, 
LexisNexis Academic, and Google Scholar.
• Key Terms:  340B, 340B Drug Pricing Program, 
340B Program, issues, intent, benefits, 
financial impact, FQHC, contract pharmacies, 
or discount outpatient drugs.
Results
• In 2016, hospitals provided nearly $38.3 billion in uncompensated care
• 45% of all Medicare acute care hospitals participate in the 340B program
• 2014–2016, the volume of purchases made through 340B more than 
doubled, expanding 125%. 
• 340B Discount Purchases =$16.2 billion in 2016 — ($12 billion in 2015)
• 340B program grew at a compound annual growth rate of 31% (2013 to 
2016).
• Average savings of 25% –50% through negotiated ceiling / sub-ceiling price
https://www.aha.org/system/files/2018-01/2017-uncompensated-care-factsheet.pdf
Growth of the 340B Program
Benefits Realized with 340B Program:
• Better access to medications to the un/underinsured population - sliding scale fee.
• Increases revenue for affiliated provider = reduced acquisition costs for meds
• Hospital overall profitability enhanced due to patient compliance and reduced 
hospitalizations within 30 days of discharge.
• There is an impact – noted in 340B Health Fiscal Year 2015 Study:
▫ 340B Disproportionate Share Hospitals (DSH) - responsible for 60% of all uncompensated 
and unreimbursed care while they make up only 38% of acute care hospitals studied
▫ 340B DSH hospitals treated significantly more low-income patients than non-340B 
hospitals. Low-income patients made up 42% of 340B hospitals’ patient load compared 
with 27% for non-340B hospitals
▫ 340B hospitals provided 52.9% more uncompensated and unreimbursed care than non 
340B hospitals
▫ 340B DSH hospitals are more likely to offer services that are critical to low-income 
patients but are often underpaid, including outpatient alcohol and drug abuse services, 
trauma care, and care for patients with HIV/AIDS.
Limitations of the program 340B 
• 340B savings are not required to be passed on to patients directly.
• More guidance is needed to clarify what is “eligible patient” / intent
• Most savings realized in the program are related to branded 
prescription drugs.
• Limited to outpatient services.
• Complex program to participate in (especially in mixed use areas)
• Concern it drifted from its initial mission, and that hospitals are not 
always using the money to serve disadvantaged patients.
• Hospitals should be required to document how they are using dollars 
saved to meet the intent of the program
Limitations:  Debate of Scope of 340B Program
Covered Entities
• 1992 – 50 hospitals participating in 340B
• About 1/3 of all acute care hospitals in US 
participated in 340B in 2018.
• Est. drug sales to 340B-CE’s increased 125% 
from 2015-2017.
• 340B hospitals seek to preserve the current 
criteria for program eligibility and their ability 
to use revenue generated through the 
program without restrictions. 
• Argument is that the program is essential for 
maintaining the full range of services they 
provide to low-income and other patients in 
their communities. 
• Argue drug makers want to limit participation 
to save themselves money.
Manufacturer’s 
• Concern expansion of the program will result 
in manufacturers increasing prices for other 
purchasers (Conti and Bach 2013, Government 
Accountability Office 2011, Hirsch et al. 2014). 
• Manufacturers question whether all of the 
entities in the program need discounted drugs 
and whether the criteria for hospitals to 
participate in the program—such as the DSH 
adjustment percentage—should be changed 
(Government Accountability Office 2011). 
• Manufacturers seek to narrow the program’s 
focus to helping patients who are poor and 
uninsured gain access to outpatient drugs. 
Marshall University Affiliate Results (Ongoing Research)
• Cabell Huntington Hospital and Marshall Health
▫ Cabell Huntington Hospital is a 340B entity under nonprofit, disproportionate share rural hospital
▫ Marshall Health became provider based clinics of CHH
▫ Under 340B program, Marshall Pharmacy provides outpatient prescriptions
▫ Expansion of clinical services, implementation of “Meds-to-beds” program, implementation of sliding scale program to benefit 
community, development of residency program
▫ Financial impact analysis pending
▫ Expansion of number of pharmacies participating in the program
▫ Humanistic impact
• Valley Health System
▫ FQHC participant in 340B program
▫ In house pharmacies (now expanded to 3 total) with contract pharmacies
▫ Expansion of services, sliding scale program, development of residency program
▫ Financial impact analysis pending
• Thomas Health Systems
▫ Nonprofit, disproportionate share hospital
▫ Established Thomas Family Pharmacy
▫ Grew internal coverage for employee prescriptions
▫ Expanded services for all patients, implemented sliding scale program, established jointly funded clinical program
▫ Financial analysis impact pending
Discussion
• Because savings are not required to be passed on directly to patients, 
some patients who need assistance do not directly receive it
▫ Patients have to ask for sliding scale pricing
▫ Not automatic due to lack of regulatory guidance
• CE do not have to share how they use the $ and patients with 
commercial insurance and some private pay do not benefit safety net 
and often see increased copays / rates.
• Have seen growth of the plan in areas with more affluent populations 
with higher paying insurance plans (may not be target populations)
• Possible increased costs to overall system
• Created large industry for program that should be simple
CONCLUSION
1. 340B does provide benefits to Vulnerable & Underserved 
patient by:
• Expanded services 
• Increased access to healthcare. 
• Increased access to prescription drugs
2.  This type of benefit, while indirect, has fulfilled the intent 





Qualified Provider/Qualified Pharmacy/ Qualified Patient
• Records of individual’s care reside with the covered entity
• Health care services, health care professional
▫ Employed by, under contractual or other arrangements (referral)
▫ “Qualified provider”
• Entity has responsibility for care
• Service received is consistent with funding or designation status 
(hospitals exempt)
• Services must be more than dispensing
• Pharmacy is “in house” or contract pharmacy
• AIDS Drug Assistance Program (ADAP) exception
